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a  b  s  t  r  a  c  t
Candida albicans utilizes arachidonic acid (AA) released during the course of infection (Can-
didiasis) from phospholipids of infected host cell membranes and synthesizes extracellular
prostaglandin(s)  which play an important role in hyphae formation and host cell damage.
C.  albicans bioﬁlms secrete signiﬁcantly more prostaglandin(s) and evidence suggests that
Candida bioﬁlms have dramatically reduced susceptibility to majority of antifungal drugs.
AA  inﬂuences the saturation level of lipids and ﬂuidity of yeast cell membranes. Therefore
the  aim of this study was to evaluate the effect of AA alone or in combination with anti-
fungal  agents on bioﬁlm formation and production of prostaglandin (PGE2) in C. albicans, C.
parapsilosis, C. glabrata, C. tropicalis, and C. albicans amphotericin B resistant strain (AmBR).
Maximum  bioﬁlm formation was found to be in the case of C. albicans compared to C. non-
albicans  species. However, among the non-albicans species C. tropicalis exhibited highest
bioﬁlm  formation. Treatment with AA in combination with subinhibitory concentrations of
ﬂuconazole and terbinaﬁne separately exhibited signiﬁcant (p < 0.05) reduction in bioﬁlm
formation  against C. glabrata, C. parapsilosis, C. tropicalis and AmBR as compared to theirindividual  effect. Further, these two antifungal agents in combination with AA caused an
increase  in production of prostaglandin from fungal cell itself which was signiﬁcant (p < 0.05)
in case of all the strains tested.
to  aggravation of infection. Evidence suggests that Candida
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virulence and antifungal resistance has been studied in
detail.1 Candida non-albicans species like C. parapsilosis and C.
tropicalis  have also been found as bioﬁlm forming pathogens
in  recent past.2,3
Candida albicans has been reported to be responsible for the
release  of arachidonic acid (AA) from the host cells during
infections4,5 which may  modulate the cell growth, morpho-
genesis and invasiveness of causal agent by several modes.
AA  is a precursor for the production of eicosanoids which play
an  important role in morphogenesis and bioﬁlm formation.
Prostaglandin E2 (PGE2) is a primary product of AA metabolism
in  most of the eukaryotic cells that has also been reported in
pathogenic  fungi as well.6,7 Enhanced prostaglandin produc-
tion  during fungal infections could be one of the important
factors in promoting colonization as well as chronic infections.
The  shift in host immune response toward increased coloniza-
tion  and chronic infections is due to PGE2, which has ability to
elicit  both pro- and anti-inﬂammatory responses depending
upon  the host cells.8,9
Exogenous AA has been reported to increase PGE2 level
signiﬁcantly in C. albicans whereas the behavior of Candida
non-albicans species and resistant strains in presence of AA is
not much  studied till now.8–10 The studies related to determin-
ing  the level of PGE2 in C. albicans and C. non-albicans species in
presence of AA may  help in understanding the bioﬁlm form-
ing  capacity. The purpose of the present study was  to compare
the  bioﬁlm formation capacity and the level of prostaglandin
secretion of the C. albicans and Candida non-albicans species in
the presence of AA and known antifungal agents. The study
also  explores the pattern and amount of bioﬁlm formation and
the  amount of prostaglandin secreted by a laboratory induced
amphotericin B resistant C. albicans strain (AmBR).11
Materials  and  methods
Candida  strains  used
Five species of Candida were  used in this study. Out of these
four  species viz. C. albicans (ATCC-10231), C. glabrata (ATCC-
MYA2950), C. parapsilosis (ATCC-22019), and C. tropicalis (ATCC-
750)  were  purchased from ATCC (American type cell culture)
while  the ﬁfth was  an amphotericin B resistant strain of C.
albicans  (AmBR) developed earlier in our laboratory.11
Media  used  and  growth  conditions
All the test strains maintained on Sabouraud dextrose agar
were  grown in yeast extract peptone and dextrose (YPD)
medium  (Difco BD, USA) for 24 h at 28 ◦C in an incubator shaker
(180  rpm). The yeast cells were  harvested, washed twice with
0.15  M phosphate-buffered saline (PBS, pH 7.4) and suspended
in  10 ml  of same buffer.
Antifungal  susceptibility  in  vitroThe minimal inhibitory concentrations (MICs) of ﬂuconazole
(Sigma  Aldrich, USA) and terbinaﬁne (Biomole, USA) against
all  the ﬁve strains (as above) were determined by broth micro-
dilution  method as per guidelines of CSLI (formerly NCCLS)12 1 4;1  8(3):287–293
using RPMI 1640 (Sigma Aldrich, USA) buffered with MOPS
(Sigma  Chemical Co.) in 96-well tissue culture plates with
positive  and negative growth as well as drug controls. The
test  antifungals terbinaﬁne and ﬂuconazole were  dissolved
in  DMSO (Merck, Germany) at a concentration of 2 mg/ml
and  0.64 mg/ml  respectively, diluted twofold and tested
against 2 × 103 cells per ml  of the test fungi. The micro-titer
plates were  incubated at 35 ◦C in a moist, dark chamber and
MICs  were recorded spectrophotometrically (Spectra Max,
Molecular  devices, USA) at 490 nm after 48 h incubation.
MICs of ﬂuconazole and terbinaﬁne were  determined
against bioﬁlm formation by using the standard CLSI micro
dilution  protocol M27-A.12–14 Brieﬂy, 1–5 × 103 cells/ml were
incubated in RPMI 1640 buffered with MOPS under shaking
condition at 37 ◦C for 90 min  and the plates were  washed
three times with PBS to remove non-adherent cells. The
test  antifungals ﬂuconazole (32–0.25 g/ml) and terbinaﬁne
(100–0.39 g/ml) were diluted twofold in a replica plate and
the  whole contents transferred to the plates having the culture
of  bioﬁlms and incubated for 48 h at 37 ◦C. Subsequently the
plates  containing Candida bioﬁlms were washed thrice with
PBS  and 50 l of XTT salt solution (1 mg/ml  in PBS) and 4 l of
menadione solution (1 mM in acetone; Sigma) added to each
well,  incubated at 37 ◦C for 5 h, and XTT formazan measured
in  the supernatant medium at 490 nm by using a spectropho-
tometer (Molecular Devices, USA) where ≥80% decrease in
formazan  (OD at 490 nm)  was  taken as MIC. The experiment
was  done in duplicate and repeated three times on different
occasions.
Bioﬁlm  formation
All the strains were subjected to bioﬁlm formation under the
following  growth conditions separately: YNB with 50 mM glu-
cose,  YNB with 50 mM Glucose supplemented with 500 M
AA  (Sigma Aldrich, USA), YNB with 50 mM glucose added
subinhibitory concentration (1/2MIC) of ﬂuconazole, YNB with
50  mM glucose added 1/2MIC terbinaﬁne, YNB and 50 mM glu-
cose  supplemented with 1/2MIC ﬂuconazole and AA and YNB
supplemented with 50 mM glucose, 1/2MIC terbinaﬁne and
AA.  Here it may  be mentioned that subinhibitory concentra-
tion  (1/2MIC) of both the drugs ﬂuconazole and terbinaﬁne
against bioﬁlm were used (Table 1). Bioﬁlm formation was
carried  out in 96 well culture plates.15 Two-hundred l fun-
gal  suspensions (1 × 106 cells) of all the test strains in the
above  medium were poured in 96 well tissue culture plates
separately, kept under mild shaking condition for 90 min  and
subsequently  the non-adherent cells were washed out with
PBS.  Then 200 l media containing appropriate growth condi-
tions  as above was  added in each well and incubated at 37 ◦C
for  48 h.16,17
Bioﬁlm  quantitation
Quantitation of Candida bioﬁlms was  performed by using
2,3-bis  (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)
carbonyl]-2H-tetrazolium hydroxide (XTT; Sigma Aldrich,
USA)  reduction assay where the water-soluble formazan
product was  measured at 490 nm.17,18 Following the bioﬁlm
formation phase, culture plates containing Candida bioﬁlms
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Table 1 – Minimal inhibitory concentration (MIC) of antifungal agents against different species and strains of Candida.
Strains Terbinaﬁne (MIC in g/ml) Fluconazole (MIC in g/ml)
Planktonic Bioﬁlm Planktonic Bioﬁlm
MIC 1/2MIC MIC 1/2MIC MIC 1/2MIC MIC 1/2MIC
C. albicans 18.3 9.2 >100 100 0.36 0.18 4.0 2.0
AmBR 0.23 0.12 50.0 25.0 0.61 0.30 32.0 16.0
C. glabrata 72.0 36.0 >100 100 3.31 1.65 32.0 16.0
C. parapsilosis 0.29 0.14 50.0 25 0.74 0.37 2.0 1.0
C. tropicalis 68.0 34.0 >100 100 0.19 0.09 0.25 0.12
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1  mg/ml  in PBS) and 4 l of menadione solution (1 mM in ace-
one;  Sigma) added to each well. The plates were incubated at
7 ◦C for 5 h and XTT formazan measured in the supernatant
edium at 490 nm by using a spectrophotometer (Molecular
evices, USA). The experiment was  done in duplicate and
epeated  three times on different occasions.
luorescence  microscopy
o study the bioﬁlm formation ﬂuorescence microscopy was
erformed  in six well tissue culture plates and the images
ere  obtained on Leica DM2500 Fluorescence microscope.
rieﬂy, bioﬁlms of above strains were grown in six well
issue  culture plates in RPMI 1640 with l-glutamine and
.165  M MOPS under different conditions of media as men-
ioned  above. After incubation each well was washed with
PBS,  stained with 100 mg/ml  ﬂuorescein diacetate (FDA;
igma  Aldrich, USA) and 50 mg/ml  propidium iodide (PI; Sigma
ldrich,  USA) for 3 h and viewed under microscope.19
rostaglandin  E2 quantitation
upernatant obtained (after 48 h) from the bioﬁlm culture of
ll  the strains under different growth conditions as mentioned
bove  were subjected to PGE2 estimation. Prostaglandin E2
xpress EIA kit (Cayman Chemicals) was  used according to
anufacturer’s instructions. Brieﬂy, cell culture supernatant
as  used directly for prostaglandin estimation and appro-
riate  standards and controls were  run simultaneously to
btain  a standard curve. Each sample was  assayed in triplicate
nd  the experiments were  repeated three times on different
ccasions.10 Sample concentrations were  calculated on the
asis  of standard curve (plotted against standards versus PGE2
oncentration) and the data represented is the average of three
xperiments.
tatistical  analysis
ll experiments were performed in triplicate unless stated
therwise. The t-test was  performed to determine the signiﬁ-
ance  of the data sets.esults  and  discussion
andidiasis is one of the common fungal infections in humans
nd  C. albicans being endogenous has been considered amajor  causative agent but in recent past, but Candida non-
albicans  species have also marked their presence as frequent
pathogens. The major clinical impact generated by Candida
species  is their ability to form bioﬁlms which results in
increased resistance to antifungal therapy and the ability of
yeast  cells within the bioﬁlms to withstand host immune
defences. Over and above it is interesting to note that there
are  species-speciﬁc variations in Candida bioﬁlm morphology
and  formation capacity.1–3 Considering this, two antifungals,
ﬂuconazole and terbinaﬁne were included in this study know-
ing  the fact that the two are chemically different and yet block
the  synthesis of ergosterol.
Antifungal  susceptibility  against  ﬂuconazole  and
terbinaﬁne
MICs were  determined by CLSI method12 for ﬂuconazole and
terbinaﬁne  against both planktonic and bioﬁlm cells of C.
albicans,  C. glabrata, C. parapsilosis, C. tropicalis and AmBR. In
the  present study ﬂuconazole (0.19–32 g/ml) exhibited over-
all  better spectrum of efﬁcacy as compared to terbinaﬁne
(0.23–>100 g/ml) against planktonic cells as well as bioﬁlm
cells  (Table 1). However terbinaﬁne exhibited an edge over ﬂu-
conazole in case of AmBR and C. parapsilosis (Table 1).
Bioﬁlm  formation
In the present study, bioﬁlm formation was  studied in C. albi-
cans  and Candida non-albicans species (C. glabrata, C. tropicalis,
and  C. parapsilosis) and a laboratory developed amphotericin
B  resistant (AmBR) strain of C. albicans.11 Polystyrene 96-well
cell  culture plates were  used for bioﬁlm formation in YNB
media,  which was  measured by XTT reduction assay (Fig. 1). It
is known that bioﬁlms exhibit resistance against antifungals
compared to planktonic cells; thus, the sub-inhibitory concen-
trations  (1/2MIC, Table 1) of antifungal agents may  have several
important  implications on planktonic cells destined to form
bioﬁlms.14,18,19 The inﬂuence of different treatments (growth
conditions) was compared with the formation of bioﬁlms in
YNB  alone which was considered as 100% for each of the
ﬁve  strains tested. In the present study YNB supplemented
with AA (500 M) did not affect the bioﬁlm formation so
the  results indicate that 500 M AA has no inﬂuence on the
viability  of the bioﬁlms. The subinhibitory concentration of
ﬂuconazole  caused reduced bioﬁlm formation in case of C.
parapsilosis  (71.9% ± 2.9, p < 0.05) and the resistant strain AmBR
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Table 2 – Bioﬁlm formation (in %) under the inﬂuence of different media treatment.
Strains % growth of bioﬁlm under the inﬂuence of different media
YNBa+AA YNBa+1/2FLZ YNBa+1/2TER YNBa+AA+1/2FLZ YNBa+AA+1/2TER
C. albicans 95.9 ± 1.2 96.4 ± 1.02 93.6 ± 1.4 91.0 ± .2.4 86.1 ± 1.8
AmBR 94.1 ± 1.7 80.8 ± 3.2 47.2 ± 1.6 61.4 ± 1.9 26.5 ± 1.2
C. glabrata 93.6 ± 1.4 91.9 ± 2.9 62.3 ± 1.4 82.6 ± 2.3 31.6 ± 1.4
C. parapsilosis 90.3 ± 1.8 71.8 ± 2.9 42.7 ± 1.6 60.6 ± 2.2 23.0 ± 1.3
C. tropicalis 99.1 ± 1.1 96.6 ± 1.2 93.1 ± 1.4 88.6 ± 2.3 48.9 ± 2.4a Bioﬁlm formation in YNB alone was considered as control (100%).
(81.9% ± 3.2, p < 0.05). The bioﬁlms of C. albicans as well as C.
non-albicans  species are known to exert resistance against
many  antifungal agents including ﬂuconazole,2,3 which has
also  been reported to reduce bioﬁlm formation in clinically
isolated ﬂuconazole susceptible and resistant strains of C.
albicans.17 However, in the present study a reduction in bioﬁlm
formation  was  evident in case of AmBR only (Fig. 1 and Table 2).
The  subinhibitory concentration of terbinaﬁne caused signif-
icantly  (p < 0.0005) reduced bioﬁlm formation in case of C.
parapsilosis  (42.7% ± 1.6,), AmBR (47.8% ± 1.6) and C. glabrata
(61.2%  ± 1.4) while in case of remaining two strains non-
signiﬁcant reduction was  noticed (p > 0.05, Table 2).
It is encouraging to note that both the antifungals when
tested  in combination with AA resulted in further inhibition
in  bioﬁlm formation as compared to either of the two agents
(antifungal and AA) tested alone. Our results exhibit that ﬂu-
conazole  and terbinaﬁne when tested in combination with
AA  caused least bioﬁlm formation in case of C. parapsilosis
followed by AmBR and C. glabrata. However, this effect was
more  pronounced (p < 0.0005) with terbinaﬁne in C. parapsilosis
(23%  ± 1.3), AmBR (26.5% ± 1.2) and in case of C. glabrata it was
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Fig. 1 – XTT reduction assay of bioﬁlm.
Bioﬁlm formation by Candida albicans, non-albicans, and
AmBR  under the inﬂuence of different media treatment was
estimated  by XTT assay. Bioﬁlm formation in YNB alone
was  considered as control. Further 1/2MIC of ﬂuconazole
(FLZ) and terbinaﬁne (TER) were  supplemented in medium
individually or in combination with arachidonic acid (AA).
Results  exhibit that FLZ and TER affects bioﬁlm formation
but  it was  more  pronounced when tested in combination
with AA in comparison to control (p < 0.005) and least
bioﬁlm formation was  observed in case of C. parapsilosis
followed by AmBR and C. glabrata. However, this effect was
more pronounced with TER (p < 0.005) in comparison to FLZ.31.6%  ± 1.4 (Fig. 1 and Table 2). In addition to this terbinaﬁne
with  AA also reduced bioﬁlm formation of C. tropicalis indi-
cating  that terbinaﬁne with AA was the best combination in
reducing  bioﬁlm formation against test strains as well as resis-
tant  strain AmBR (Table 2).
Fluorescence  microscopy  for  bioﬁlm  evaluation
The bioﬁlm cells of the test Candida strains were  investigated
by  staining with FDA and PI and viewed under ﬂuorescence
microscope. The live and dead cells of bioﬁlms were  distin-
guished  by green (FDA) and red (PI) ﬂuorescence respectively
indicating the presence of both viable and dead cells in varied
amounts  with regard to various treatments. The bioﬁlm
formation of all the test strains in YNB alone (Fig. 2A1–E1)
were  used as respective control where green ﬂuorescent
images were  observed suggesting the viability of bioﬁlm
cells.  Treatment of bioﬁlms with various test agents like AA
alone,  1/2MIC ﬂuconazole, 1/2MIC terbinaﬁne and 1/2MIC of
antifungals  combination with AA caused varied ﬂuorescence
(Fig.  2). The subinhibitory concentration (1/2MIC) of ﬂucona-
zole  and terbinaﬁne also exhibited some changes (Fig. 2A3–E3
and  A4–E4) in ﬂuorescence as compared to their respective
controls which is in agreement with the results of XTT
assay  (Fig. 1). As expected the subinhibitory concentration of
ﬂuconazole  and terbinaﬁne supplemented with AA resulted
in  signiﬁcant suppression of bioﬁlm formation (Fig. 2A5–E5
and  A6–E6). Fluorescence microscopy of test strains with
different  treatments exhibited that 1/2MIC of antifungals
in  combination with AA affect the bioﬁlm formation of all
the  test strains, which was greater in case of terbinaﬁne as
compared  to ﬂuconazole (Fig. 2).
PGE2 production  by  bioﬁlms  of  C.  albicans  and  C.
non-albicans  strains
The planktonic and bioﬁlm forms of C. albicans have been
reported to produce eicosanoids particularly prostaglandin
itself and/or in the presence of AA which is greater in
bioﬁlms.10 Prostaglandins have been known to be poten-
tial  molecules to mediate cross talk between host and
pathogen resulting in down-regulation of host immunological
responses. Prostaglandins also play an important role in the
persistence  of fungal pathogen in immunocompetent hosts
resulting  in chronic infections. As stated above enhanced
prostaglandin production has been observed in C. albicans
bioﬁlm10 whereas its production in bioﬁlms produced by Can-
dida  non-albicans species and drug resistant strain has not
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Fig. 2 – Fluorescence microscopy of bioﬁlm: ﬂuorescence microscopy comparison of bioﬁlms grown in presence and
absence of arachidonic acid (AA) treated with subinhibitory concentration of ﬂuconazole and terbinaﬁne exhibited that least
bioﬁlm formation was  observed in case of C. glabrata (Figs. B5 and B6), C. parapsilosis (Figs. C5 and C6) and AmBR (Figs. E5
and E6) compared to that in case of C. albicans (Figs. A5 and A6). The test strains with different treatments exhibited that
1/2MIC of antifungals with AA affect the bioﬁlm formation of all test strains and among all treatments 1/2MIC of terbinaﬁne
with AA has greater effect than 1/2MIC ﬂuconazole with AA. This result also suggests that terbinaﬁne increases the
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et been studied. The amount of PGE2 secreted by the test
trains  under control condition (YNB alone) for C. albicans
141  pg/ml, ±6.2), C. glabrata (57.3 pg/ml, ±1.3), C. parapsilosis
28.1  pg/ml, ±1.1), C. tropicalis (29.6 pg/ml, ±2.4) and AmBR
100.2  pg/ml, ±2.1) was  considered as basal concentration and
he  amount of PGE2 was  calculated after subtracting the basal
oncentration (Fig. 3). An increase in PGE2 synthesis was  noted
or  C. albicans (1387 ± 15.0 pg/ml), AmBR (1878 ± 11.0 pg/ml),
.  parapsilosis (1189.3 ± 13.2 pg/ml), C. glabrata (1123.0 ± 15.5)
nd  C. tropicalis (1846 ± 15.3 pg/ml) when grown in YNBsupplemented with AA (p < 0.005). These results suggest that
AA  could have been incorporated into the phospholipids of
yeasts,  inﬂuencing the saturation level and ﬂuidity of yeast
cell  membranes. Inﬂuence of AA on cell membrane phospho-
lipids  unsaturation and ergosterol content has been reported
recently.10,20 The reduced ergosterol content of amphotericin
11B  resistant strain could have been saturated with phos-
pholipids incorporated by AA. Therefore increased amount
of  membrane phospholipids enables AmBR to produce more
PGE2 than its parent strain.
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Table 3 – PGE2 level (pg/ml) estimated under the inﬂuence of arachidonic acid (AA).
Strains PGE2 level (pg/ml) in different conditions
YNB+AAa YNB+AA+1/2MIC FLZ YNB+AA+1/2MIC TER
C. albicans 1387 ± 15.0 2157.3 ± 26.1 (p < 0.0001) 1655.3 ± 14.1 (p < 0.0001)
AmBR 1878 ± 11.0 1935 ± 16.5 (p < 0.005) 2114 ± 12.2 (p < 0.0001)
C. glabrata 1123.0 ± 15.5 1174.3 ± 9.2 (p < 0.05) 1374.3 ± 16.5 (p < 0.0001)
C. parapsilosis 1189.3 ± 13.2 1944 ± 14.5 (p < 0.0001) 1942.3 ± 2.5 (p < 0.0001)
C. tropicalis 1846 ± 15.3 1966.6 ± 14.0 (p < 0.005) 1858 ± 9.1 (p < 0.1)
ison.a PGE2 level in YNB+AA was used as basal concentration for compar
In this experiment the results show that prostaglandin
production is enhanced when AA was  supplemented
with subinhibitory concentration of ﬂuconazole, C. albicans
exhibited  2157.3 ± 26.1 pg/ml PGE2 followed by C. tropicalis
(1966.6 ± 14.0 pg/ml), C. parapsilosis (1944 ± 14.5 pg/ml), AmBR
(1935  ± 16.5 pg/ml) and C. glabrata (1174.3 ± 9.2 pg/ml) (Fig. 3
and  Table 3). PGE2 production in the presence of AA with
subinhibitory concentration (1/2MIC) of terbinaﬁne was  more
pronounced  (p < 0.0005; Fig. 3 and Table 3) against AmBR
(2114  ± 12.2 pg/ml) and C. glabrata (1374.3 ± 16.5 pg/ml). The
present  results open a new dimension in prostaglandin
research as Candida non-albicans and C. albicans drug-resistant
strain (AmBR) exhibited a notable difference in production of
PGE2 individually.The variation in PGE2 production in bioﬁlms of the different
test  strains could be indicative of their persistence in host tis-
sues. The level of PGE2 in all test strains, including AmBR, was
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Fig. 3 – PGE2 level estimation of C. albicans and
non-albicans bioﬁlms.
The  level of PGE2 produced by Candida albicans and
non-albicans bioﬁlm in different media treatment was
estimated after 48 h incubation. Synthesis in YNB medium
was used as control, further supplemented with
arachidonic acid (AA), 1/2MIC of ﬂuconazole (FLZ) and
terbinaﬁne (TER) individually. Result exhibited that PGE2
formation was  increased in the presence of 1/2MIC
antifungals and it is more  pronounced in C. tropicalis and
AmBR  against TER. The level of PGE2 in all test strains
including AmBR, was  found to be enhanced under medium
of  YNB supplemented with AA, 1/2MIC FLZ (p < 0.0005) and
AA, 1/2MIC TER (p < 0.0005). PGE2 level was  estimated by
ELISA method (Cayman Kit). Result suggested that AA
enhanced  PGE2 production in the presence of subinhibitory
concentration of antifungals (1/2MIC).
rfound to be enhanced under medium of YNB with AA+1/2MIC
ﬂuconazole and with AA+1/2MIC terbinaﬁne (p < 0.0005, Fig. 3).
This  can be explained by the fact that AA increases suscep-
tibility  of C. albicans as well as Candida non-albicans species
against  antifungal agents and may  affect the prostaglandin
production as well. Thus, it is evident from the results that
the  exposure to antifungal agents enhances the productions of
PGE2 to a greater extent in bioﬁlms which may  be responsible
for  development of resistance against antifungal agents.
Conclusion
The main general conclusion from this study is that the
effect  of subinhibitory concentrations of antifungal agents on
bioﬁlm formation is dependent on the type of antifungal agent
and  fungal strain used. Fluconazole and terbinaﬁne when
tested  in combination with AA caused least bioﬁlm forma-
tion  in case of C. parapsilosis followed by AmBR and C. glabrata.
However, this effect was  more  pronounced with terbinaﬁne
in  terms of antifungal activity as well as reduced bioﬁlm
formation. Our results further suggest that AA could have
been  incorporated into the phospholipids of yeasts, inﬂuenc-
ing  the saturation level and ﬂuidity of yeast cell membranes.
Further, the enhanced prostaglandin production in Candida
non-albicans and drug resistant C. albicans as compared to C.
albicans  opens a new area of research to investigate the role
of  prostaglandin in antifungal resistance development and
pathogenesis.
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